Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14

作者：

Shimbashi, Reiko ^{[1
,2
]}

Suzuki, Motoi ^{[1
,2
]}

Chang, Bin ^{[1
]}

Watanabe, Hiroshi ^{[3
]}

Tanabe, Yoshinari ^{[4
]}

Kuronuma, Koji ^{[5
]}

Oshima, Kengo ^{[2
]}

Maruyama, Takaya ^{[6
]}

Takeda, Hiroaki ^{[7
]}

Kasahara, Kei ^{[8
]}

Fujita, Jiro ^{[9
]}

Nishi, Junichiro ^{[10
]}

Kubota, Tetsuya ^{[11
]}

Tanaka-Taya, Keiko ^{[1
]}

Matsui, Tamano ^{[1
]}

Sunagawa, Tomimasa ^{[1
]}

Oishi, Kazunori ^{[1
,12
]}

机构：

[1] Natl Inst Infect Dis, Tokyo, Japan

[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan

[3] Kurume Univ, Sch Med, Fukuoka, Japan

[4] Niigata Prefectural Shibata Hosp, Niigata, Japan

[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan

[7] Yamagata Saisei Hosp, Yamagata, Japan

[8] Nara Med Univ, Nara, Japan

[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan

[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan

[11] Kochi Univ, Kochi Med Sch, Kochi, Japan

[12] Toyama Inst Hlth, Toyama, Japan

来源：

EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期

关键词：

PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;

D O I：

10.3201/eid2610.191531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.

引用

页码：2378 / 2386

页数：9

共 50 条

[21] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
Lawrence, Hannah
Pick, Harry
Baskaran, Vadsala
Daniel, Priya
Rodrigo, Chamira
Ashton, Deborah
Edwards-Pritchard, Rochelle C.
Sheppard, Carmen
Eletu, Seyi D.
Litt, David
Fry, Norman K.
Rose, Samuel
Trotter, Caroline
McKeever, Tricia M.
Lim, Wei Shen
PLOS MEDICINE, 2020, 17 (10)
[22] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
Nielsen, Katrine Finderup
Nielsen, Lise Birk
Lomholt, Frederikke Kristensen
Norgaard, Sarah Kristine
Slotved, Hans-Christian
Dalby, Tine
Fuursted, Kurt
Jorgensen, Charlotte Svaerke
Valentiner-Branth, Palle
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (12) : 1473 - 1477
[23] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study
Katrine Finderup Nielsen
Lise Birk Nielsen
Frederikke Kristensen Lomholt
Sarah Kristine Nørgaard
Hans-Christian Slotved
Tine Dalby
Kurt Fuursted
Charlotte Sværke Jørgensen
Palle Valentiner-Branth
European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 1473 - 1477
[24] Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
Nielsen, Katrine Finderup
Nielsen, Lise Birk
Dalby, Tine
Lomholt, Frederikke Kristensen
Slotved, Hans-Christian
Fuursted, Kurt
Harboe, Zitta Barrella
Jorgensen, Charlotte Svaerke
Valentiner-Branth, Palle
EMERGING INFECTIOUS DISEASES, 2024, 30 (06) : 1164 - 1172
[25] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Masuda, Toshihiro
Akamatsu, Taisuke
Nakatani, Eiji
Tamura, Kanami
Takahashi, Shingo
Tanaka, Yuko
Watanabe, Hirofumi
Endo, Yoshinari
Suzuki, Takahito
Noguchi, Rie
Saigusa, Mika
Yamamoto, Akito
Shishido, Yuichiro
Akita, Takefumi
Morita, Satoru
Asada, Kazuhiro
Shirai, Toshihiro
EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[26] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in Brazilian elderly
Simonsen, V
Brandao, AP
Brandileone, MCC
Yara, TI
Di Fabio, JL
Lopes, MH
Jacob, W
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2005, 38 (02) : 251 - 260
[27] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
Shiramoto, Masanari
Hanada, Ryuzo
Juergens, Christine
Shoji, Yasuko
Yoshida, Mizuki
Ballan, Barry
Cooper, David
Gruber, William C.
Scott, Daniel A.
Schmoele-Thoma, Beate
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
[28] EVALUATION OF PNEUMOCOCCAL TITERS AND RESPONSE TO 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CHILDREN WITH COUGH
Anthony, K.
Urrego, F.
PEDIATRIC PULMONOLOGY, 2014, 49 : S78 - S78
[29] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
Gouveia, Miguel
Jesus, Goncalo
Ines, Monica
Costa, Joao
Borges, Margarida
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
[30] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
Jiang, Yiling
Gauthier, Aline
Keeping, Sam
Carroll, Stuart
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927

← 1 2 3 4 5 →